With regard to TKI drug combinations, in a 21 patient phase I study of Erlotinib plus Nivolumab in EGFR mutant NSCLC, promising efficacy was observed with a PFS of 29.4 weeks and an ORR of 19% [20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.